Eris Lifesciences Ltd vs Procter Gamble Health Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1335 as of 18 May 16:01 . The P/E Ratio of ERIS Lifesciences Ltd changed from 23.1 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 18.86% over 5 yearsThe P/E Ratio of Procter & Gamble Health Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of ERIS Lifesciences Ltd changed from ₹ 8207 crore on March 2021 to ₹ 19287 crore on March 2025 . This represents a CAGR of 18.64% over 5 yearsThe Market Cap of Procter & Gamble Health Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of ERIS Lifesciences Ltd for the Dec '25 is ₹ 807.59 crore as compare to the Sep '25 revenue of ₹ 795.5 crore. This represent the growth of 1.52% The revenue of Procter & Gamble Health Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of ERIS Lifesciences Ltd for the Dec '25 is ₹ 264.51 crore as compare to the Sep '25 ebitda of ₹ 291.3 crore. This represent the decline of -9.2% The ebitda of Procter & Gamble Health Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of ERIS Lifesciences Ltd changed from ₹ 89.55 crore to ₹ 108.83 crore over 7 quarters. This represents a CAGR of 11.79% The net profit of Procter & Gamble Health Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The dividend payout of ERIS Lifesciences Ltd changed from 129.35 % to 0 % over 5 quarters. This represents a CAGR of -100.00% The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00% .

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007.
Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective.

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

FAQs for the comparison of ERIS Lifesciences Ltd and Procter & Gamble Health Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Procter & Gamble Health Ltd?

Market cap of ERIS Lifesciences Ltd is 19,038 Cr while Market cap of Procter & Gamble Health Ltd is 8,775 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Procter & Gamble Health Ltd?

The stock performance of ERIS Lifesciences Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Procter & Gamble Health Ltd?

As of May 18, 2026, the ERIS Lifesciences Ltd stock price is INR ₹1373.95. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹5286.55.

How do dividend payouts of ERIS Lifesciences Ltd and Procter & Gamble Health Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.